“The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently, reflecting sustained uptake and confidence in the clinical value of EKTERLY as the first and only oral on-demand treatment for hereditary angioedema,” said Ben Palleiko, CEO of KalVista (KALV). “We also recently launched EKTERLY in Germany, with very positive initial demand. And with our most recent approval in Australia, we now hold five regulatory approvals and are on our way to making EKTERLY a truly global product. With the successful closing of our recent $144 million convertible note offering, we have the financial resources to continue advancing our global launch strategy and building long-term growth.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Buy Rating for KalVista Pharmaceuticals Driven by Strong Ekterly Uptake and Optimistic Revenue Projections
- KalVista’s Pediatric HAE Study: A Potential Game-Changer?
- KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment?
- KalVista price target lowered to $29 from $36 at BofA
- KalVista presents new data on Ekterly in Europe